Fibromyalgia – European Clinical Trials Information Network

Study of rituximab for reducing pain in patients with fibromyalgia caused by autoantibodies

Thu, 30 Apr 2026 13:08:39 +0000

This study is looking at fibromyalgia, a condition that causes widespread pain throughout the body along with other symptoms like tiredness and sleep problems. The study will test whether a medicine called rituximab can help reduce pain in people who have fibromyalgia. Rituximab is a medicine that affects the immune system, which is the body’s defense system. In this study, participants will also receive other medicines to help manage symptoms during the study, including paracetamol for pain relief, methylprednisolone which is a medicine that reduces inflammation, and cetirizine dihydrochloride which is commonly used for allergies. The purpose of this study is to find out if rituximab treatment can reduce the average daily pain that people with fibromyalgia experience.

Participants in this study must have been diagnosed with fibromyalgia within the past two years and must have significant pain levels. They must also have specific antibodies in their blood that are associated with fibromyalgia. These antibodies are proteins made by the immune system that may be causing some of the pain symptoms. The study will measure how much pain decreases sixteen weeks after participants receive the rituximab treatment. Rituximab will be given through a tube inserted into a vein, which is called an infusion. The treatment period will last for one day, and participants will be followed for sixteen weeks after receiving the medicine.

During the study, researchers will measure pain levels using a scale where participants mark how much pain they feel. They will also use questionnaires to understand how fibromyalgia affects daily life and whether participants feel their condition has improved. The study will also look at changes in the antibodies in the blood to see if there is a connection between these antibodies and pain levels. The entire study is expected to run from early 2026 to early 2027.

Study on Psilocybin’s Effect on Pain in Fibromyalgia Patients

Wed, 29 Apr 2026 15:03:09 +0000

This clinical trial is focused on studying the effects of psilocybin on individuals with fibromyalgia, a condition characterized by widespread pain and tenderness in the body. The study aims to explore how low doses of psilocybin, a compound found in certain mushrooms, can influence pain perception in people with fibromyalgia. Participants will receive either psilocybin or a placebo in the form of capsules.

The purpose of the study is to assess whether psilocybin can help reduce pain in fibromyalgia patients and to examine its effects on mood, thinking, and memory. The study will also look at how psilocybin might affect certain proteins in the body, such as BDNF (Brain-Derived Neurotrophic Factor), which is involved in nerve growth and function. Additionally, researchers will investigate if psilocybin can influence levels of inflammation-related substances in the blood.

Participants will take part in several sessions where they will receive either psilocybin or a placebo. During these sessions, various assessments will be conducted to evaluate changes in pain, mood, and other factors. The study will also explore whether suggestions given under hypnosis can alter the effects of psilocybin on pain. The trial is expected to continue until mid-2026, with recruitment starting in mid-2024.

Study on Pain Relief for Fibromyalgia Patients with Trapezius Myofascial Syndrome Using Bupivacaine, Triamcinolone, and Sodium Chloride

Wed, 29 Apr 2026 15:03:07 +0000

This clinical trial is focused on studying the treatment of pain in patients with fibromyalgia, a condition characterized by widespread pain and tenderness. Specifically, the study targets trapezius myofascial syndrome, which involves pain in the trapezius muscle, a large muscle extending over the back of the neck and shoulders. The treatment being tested involves an injection into the muscle using different substances: bupivacaine, a local anesthetic; triamcinolone acetonide, an anti-inflammatory medication; and a physiological saline solution, which is a simple saltwater solution. Some participants will receive a placebo.

The purpose of the study is to compare how effective these treatments are in reducing pain in the trapezius muscle and overall body pain in fibromyalgia patients. The study will involve injections guided by ultrasound to ensure accuracy, targeting specific areas between muscles in the shoulder region. Participants will receive these treatments and will be monitored over a period of time to assess changes in their pain levels and overall well-being.

Throughout the study, participants will be asked to report their pain levels and other symptoms at various intervals. This will help researchers understand the duration and effectiveness of the pain relief provided by each treatment. The study aims to provide insights into better managing pain for those suffering from fibromyalgia and trapezius myofascial syndrome.